
Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.

Your AI-Trained Oncology Knowledge Connection!


Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.

Keith T. Flaherty, MD, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy and director of clinical research, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the rationale to explore triplet therapy in BRAF V600-mutant melanoma.

Keith T. Flaherty, MD, discusses an update on overall survival in COLUMBUS, a randomized phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the COLUMBUS trial in patients with BRAF-mutant melanoma.

Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.



Published: August 2nd 2016 | Updated:

Published: August 23rd 2016 | Updated:

Published: October 11th 2016 | Updated:

Published: June 12th 2018 | Updated:

Published: August 31st 2018 | Updated:

Published: October 11th 2018 | Updated: